Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.660
+0.030 (4.76%)
At close: Mar 6, 2026, 4:00 PM EST
0.647
-0.013 (-2.00%)
After-hours: Mar 6, 2026, 4:11 PM EST
Galmed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 3.26 | 3.3 | 3.92 | 4.66 | 5.66 | 4.13 | |
| Research & Development | 3.85 | 2.98 | 3.57 | 13 | 27.22 | 26.08 | |
| Operating Expenses | 7.11 | 6.28 | 7.49 | 17.65 | 32.88 | 30.21 | |
| Operating Income | -7.11 | -6.28 | -7.49 | -17.65 | -32.88 | -30.21 | |
| Interest Expense | -0.61 | -0.61 | - | - | - | - | |
| Interest & Investment Income | 0.67 | 0.5 | 0.38 | 0.3 | 0.56 | 1.19 | |
| Currency Exchange Gain (Loss) | 0.04 | 0.04 | -0.04 | 0.04 | -0.03 | -0.12 | |
| Other Non Operating Income (Expenses) | -0.02 | -0.02 | 0.25 | -0.02 | -0.04 | -0.03 | |
| EBT Excluding Unusual Items | -7.03 | -6.36 | -6.9 | -17.34 | -32.39 | -29.17 | |
| Gain (Loss) on Sale of Investments | -1.67 | -1.16 | -0.01 | -0.53 | -0.08 | 0.4 | |
| Pretax Income | -8.7 | -7.52 | -6.91 | -17.87 | -32.47 | -28.77 | |
| Net Income | -8.7 | -7.52 | -6.91 | -17.87 | -32.47 | -28.77 | |
| Net Income to Common | -8.7 | -7.52 | -6.91 | -17.87 | -32.47 | -28.77 | |
| Shares Outstanding (Basic) | 3 | 1 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 3 | 1 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 474.24% | 303.31% | 65.23% | 2.22% | 15.59% | 0.79% | |
| EPS (Basic) | -2.71 | -8.08 | -29.95 | -127.90 | -237.59 | -243.35 | |
| EPS (Diluted) | -2.71 | -8.08 | -29.95 | -127.90 | -237.59 | -243.35 | |
| Free Cash Flow | -6.28 | -5.88 | -6.14 | -18.51 | -32.9 | -26.33 | |
| Free Cash Flow Per Share | -1.96 | -6.32 | -26.59 | -132.48 | -240.78 | -222.72 | |
| EBITDA | -7.05 | -6.2 | -7.46 | -17.62 | -32.84 | -30.17 | |
| D&A For EBITDA | 0.06 | 0.08 | 0.03 | 0.04 | 0.04 | 0.04 | |
| EBIT | -7.11 | -6.28 | -7.49 | -17.65 | -32.88 | -30.21 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.